Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease
By J. Quinn, R. Raman, Ronald G. Thomas, K. Yurko-Mauro, E. Nelson, C. V. van Dyck, J. Galvin, Jennifer A. Emond, Clifford R. Jack Jr., M. Weiner and 2 more. Journal of the American Medical Association (JAMA), 2010
784 citations recorded by the source corpus.
Context Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology. Objective To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease. Design, Setting, and Patients A randomized, double-blind, placebo-controlled trial of DHA supplementation in individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores, 14–26) was conducted between November 2007 and May 2009 at 51 US clinical research sites of the Alzheimer’s Disease Cooperative Study. Intervention Participants were randomly assigned to algal DHA at a dose of 2 g/d or to identical placebo (60% were assigned to DHA and 40% were assigned to placebo). Duration of treatment was 18 months. Main Outcome Measures Change in the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) and change in the Clinical Dementia Rating (CDR) sum of boxes. Rate of brain atrophy was also determined by volumetric magnetic resonance imaging in a subsample of participants (n = 102). Results A total of 402 individuals were randomized and a total of 295 participants completed the trial while taking study medication (DHA: 171; placebo: 124). Supplementation with DHA had no beneficial effect on rate of change on ADAS-cog score, which increased by a mean of 7.98 points (95% confidence interval [CI], 6.51–9.45 points) for the DHA group during 18 months vs 8.27 points (95% CI, 6.72–9.82 points) for the placebo group (linear mixed-effects model: P = .41). The CDR sum of boxes score increased by 2.87 points (95% CI, 2.44–3.30 points) for the DHA group during 18 months compared with 2.93 points (95% CI, 2.44–3.42 points) for the placebo group (linear mixed-effects model: P = .68). In the subpopulation of participants (DHA: 53; placebo: 49), the rate of brain atrophy was not affected by treatment with DHA. Individuals in the DHA group had a mean decline in total brain volume of 24.7 cm3 (95% CI, 21.4–28.0 cm3) during 18 months and a 1.32% (95% CI, 1.14%–1.50%) volume decline per year compared with 24.0 cm3 (95% CI, 20–28 cm3) for the placebo group during 18 months and a 1.29% (95% CI, 1.07%–1.51%) volume decline per year (P = .79). Conclusion Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease.
Subfields: Aquatic Science, Biochemistry, Nutrition and Dietetics
View Paper: https://www.semanticscholar.org/paper/e50de26c57a87637af4b7930f7de111930306c73
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Nutrition and Dietetics
Citations in the corpus
- Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. (2013, background): “To date, the clinical effectiveness of DHA treatment is still controversial (Freund-Levi et al., 2006; Quinn et al., 2010).”
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. (2018, neutral): “(Quinn 2010, p. 1910).”
- Omega-3 fatty acids EPA and DHA: health benefits throughout life. (2012, background): “(56) Double-blind, placebo-controlled, randomized 295; mild to moderate AD (MMSE score 14–26) supplementation group (n = 171), placebo group (n = 124) DHA (2 g/d for 18 mo) DHA supplementation led to no beneficial effect on rate of cognitive and functional decline”